Evommune, Inc.
Status: Publicly traded
Direct answer
Evommune, Inc. is publicly traded on NYSE under the ticker EVMN.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio...
Can you invest in Evommune, Inc.?
Yes. Evommune, Inc. trades publicly on NYSE as EVMN.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Evommune, Inc.
Detailed equity research is provided by MarketSnap.